Aduro Biotech, months removed from a $119 million IPO, is looking to settle down in Berkeley, leasing a four-story R&D complex as it presses forward with a pipeline of cancer treatments.
XenoPort has changed its tune on an investigational psoriasis therapy, no longer insisting that the drug's middling efficacy and alarming safety profile merit late-stage development. Instead, the biotech is dumping the drug, cutting payroll and waving away its co-founder and CEO.
Google is planning to give new businesses including its growing Life Sciences division ample breathing room as part of its reorganization, allowing the startups to run more independently as the tech titan rejigs operations and creates its parent company, Alphabet.
A group of bioengineers have developed a noninvasive, portable device that resembles a finger-worn, pulse oximeter to count white blood cells. They have three workable prototypes that are being tested with chemotherapy patients to track their immune system in real-time. The researchers aim to have an initial beta product that it can support via crowdfunding in 2017, with a product on the market potentially in 2019.
As scientists explore the genetic underpinnings of disease to help develop new diagnostics and treatments, an NIH-backed team of researchers is creating the world's largest database of human genomic variation aimed at clinical use.
Apple has been gaining momentum for its ResearchKit since rolling out the platform earlier this year, with the first batch of studies using the product recording high rates of enrollment for sponsors. The platform's success caught the eye of Yale University scientists, who are planning to use ResearchKit for a study of heart problems in children and adults.
Tiny OTC-traded micro-cap Avita Medical has won backing from the U.S. Biomedical Advanced Research and Development Authority (BARDA) of its PMA approval trial for its ReCell burn treatment device. It will get $16.9 million upfront for the study and for procurement of more than 5,000 of the devices. The ongoing pivotal trial is expected to complete enrollment by the end of the this year.
Royal Philips and the Massachusetts Institute of Technology have teamed up to develop a noninvasive means of measuring intracranial pressure to detect brain injuries. It's expected to incorporate Philips' ultrasound technology and MIT's physiological modeling.
PRA Health Sciences has joined forces with a trial site group to focus on vaccine development, hoping to speed up patient recruitment and get more clinical studies rolling.
CRO Chiltern, in the process of integrating its latest acquisition, is focusing in on endocrinology and metabolism, broadening its expertise with an eye on diabetes R&D.